Literature DB >> 16915296

Divorcing ARF and p53: an unsettled case.

Charles J Sherr1.   

Abstract

Mammalian cells that sustain oncogenic insults can invoke defensive programmes that either halt their division or trigger their apoptosis, but these countermeasures must be finely tuned to discriminate between physiological and potentially harmful growth-promoting states. By functioning specifically to oppose abnormally prolonged and sustained proliferative signals produced by activated oncogenes, the ARF tumour suppressor antagonizes functions of MDM2 to induce protective responses that depend on the p53 transcription factor and its many target genes. However, ARF has been reported to physically associate with proteins other than MDM2 and to have p53-independent activities, most of which remain controversial and poorly understood.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16915296     DOI: 10.1038/nrc1954

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  273 in total

Review 1.  Using mice to examine p53 functions in cancer, aging, and longevity.

Authors:  Lawrence A Donehower
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11-04       Impact factor: 10.005

2.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

3.  E2F1 induces p19INK4d, a protein involved in the DNA damage response, following UV irradiation.

Authors:  Abel L Carcagno; Luciana E Giono; Mariela C Marazita; Daniela S Castillo; Nicolás Pregi; Eduardo T Cánepa
Journal:  Mol Cell Biochem       Date:  2012-04-03       Impact factor: 3.396

4.  Proteomic dissection of the von Hippel-Lindau (VHL) interactome.

Authors:  Yanlai Lai; Meihua Song; Kevin Hakala; Susan T Weintraub; Yuzuru Shiio
Journal:  J Proteome Res       Date:  2011-10-11       Impact factor: 4.466

5.  Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage.

Authors:  Qian Cheng; Brittany Cross; Baozong Li; Lihong Chen; Zhenyu Li; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

6.  Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.

Authors:  Richard T Williams; Willem den Besten; Charles J Sherr
Journal:  Genes Dev       Date:  2007-08-30       Impact factor: 11.361

Review 7.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

8.  ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence.

Authors:  Linan Ha; Takeshi Ichikawa; Miriam Anver; Ross Dickins; Scott Lowe; Norman E Sharpless; Paul Krimpenfort; Ronald A Depinho; Dorothy C Bennett; Elena V Sviderskaya; Glenn Merlino
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

9.  tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.

Authors:  Kristin E N Watt; Cynthia L Neben; Shawn Hall; Amy E Merrill; Paul A Trainor
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

10.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.